Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group-Reference-Cited by-同舟云学术

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group

Published:2024-04-08 Issue:1 Volume:120 Page:60-70
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Iriyama Noriyoshi^ORCID,Iwanaga Eisaku,Kimura Yuta,Watanabe Naoki,Ishikawa Maho,Nakayama Hitomi,Sato Eriko,Tabayashi Takayuki,Mitsumori Toru,Takaku Tomoiku,Nakazato Tomonori,Tokuhira Michihide,Fujita Hiroyuki,Ando Miki,Hatta Yoshihiro,Kawaguchi Tatsuya

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12185-024-03758-4.pdf

Reference36 articles.

1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–72. https://doi.org/10.1056/NEJM199907153410306.

2. Cortes J, Pavlovsky C, Saußele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914–26. https://doi.org/10.1016/S0140-6736(21)01204-6.

3. Hehlmann R. Innovation in hematology. Perspectives: CML 2016. Haematologica. 2016;101(6):657–9. https://doi.org/10.3324/haematol.2016.142877.

4. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27. https://doi.org/10.1056/NEJMoa1609324.

5. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. https://doi.org/10.1038/s41375-020-0776-2.